Hani Luxenburg - Mediwound Chief Officer
| MDWD Stock | USD 18.24 0.58 3.28% |
Executive
Hani Luxenburg is Chief Officer of Mediwound
| Age | 51 |
| Address | 42 Hayarkon Street, Yavne, Israel, 8122745 |
| Phone | 972 7 797 14100 |
| Web | https://www.mediwound.com |
Mediwound Management Efficiency
The company has return on total asset (ROA) of (0.1664) % which means that it has lost $0.1664 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.316) %, meaning that it created substantial loss on money invested by shareholders. Mediwound's management efficiency ratios could be used to measure how well Mediwound manages its routine affairs as well as how well it operates its assets and liabilities. As of April 26, 2024, Return On Tangible Assets is expected to decline to -0.11. In addition to that, Return On Capital Employed is expected to decline to -0.29. At present, Mediwound's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.14, whereas Other Assets are forecasted to decline to about 311.2 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MBA MD | Replimune Group | 58 | |
| William II | Ocular Therapeutix | N/A | |
| Lionel Carnot | Merus BV | 49 | |
| Michael Goldstein | Ocular Therapeutix | 50 | |
| Steven Closter | Syndax Pharmaceuticals | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics Common | N/A | |
| Terry MD | Sana Biotechnology | 57 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Pamela Esposito | Replimune Group | 50 | |
| Robert McKean | Mineralys Therapeutics Common | N/A | |
| Greg Mann | NkartaInc | N/A | |
| Mark Ho | Veracyte | N/A | |
| Saterah Shamsili | Merus BV | N/A | |
| Ashraf Amanullah | InhibrxInc | 56 | |
| Kevin McManus | Syndax Pharmaceuticals | 55 | |
| Paul Bullock | Replimune Group | N/A | |
| Sarah Foster | Mineralys Therapeutics Common | N/A | |
| Philip Esq | Ocular Therapeutix | 64 | |
| Rocio Hoyos | Kronos BioInc | N/A | |
| Saurabh Sewak | Foghorn TherapeuticsInc | N/A | |
| Jeffrey MD | Ocular Therapeutix | 63 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.17 |
Mediwound Leadership Team
Elected by the shareholders, the Mediwound's board of directors comprises two types of representatives: Mediwound inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mediwound. The board's role is to monitor Mediwound's management team and ensure that shareholders' interests are well served. Mediwound's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mediwound's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Director | ||
| Lior MD, CoFounder | ||
| Vickie Driver, Director | ||
| Lior Rosenberg, Chief Medical Officer | ||
| Hani Luxenburg, Chief Officer | ||
| Cal Cohen, CEO | ||
| Aharon Yaari, Director | ||
| Pr MD, CoFounder Director | ||
| Ety MBA, Chief Officer | ||
| Ofer BSc, Chief Officer | ||
| Yaron Adv, General VP | ||
| Sharon Malka, CFO | ||
| CWS DPM, Chief Officer | ||
| Gal Cohen, CEO | ||
| Shmulik Hess, COO Officer | ||
| Stephen Wills, Director | ||
| Ety Klinger, Chief Officer | ||
| Eilon Asculai, Vice President Research & Development | ||
| Barry Wolfenson, Executive Development |
Mediwound Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mediwound a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | 127.76 M | ||||
| Shares Outstanding | 9.49 M | ||||
| Shares Owned By Insiders | 25.72 % | ||||
| Shares Owned By Institutions | 34.40 % | ||||
| Number Of Shares Shorted | 171.63 K | ||||
| Price To Earning | 16.58 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mediwound. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Mediwound's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mediwound. If investors know Mediwound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mediwound listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 2.073 | Quarterly Revenue Growth (0.54) | Return On Assets (0.17) | Return On Equity (0.32) |
The market value of Mediwound is measured differently than its book value, which is the value of Mediwound that is recorded on the company's balance sheet. Investors also form their own opinion of Mediwound's value that differs from its market value or its book value, called intrinsic value, which is Mediwound's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mediwound's market value can be influenced by many factors that don't directly affect Mediwound's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mediwound's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mediwound is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mediwound's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.